KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
Clinical trial NCT04165083 · COMPLETED
Trial details
- NCT number
- NCT04165083
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-19
- Primary completion
- 2025-10-31
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.